摘要
目的:观察肝癌患者肝移植术前使用PD-1抑制剂对肝移植术后排斥反应的影响。方法:选取2019年1月1日至2019年12月31日在复旦大学附属中山医院行肝移植且移植前接受过PD-1抑制剂治疗的肝癌患者,共12例。检测其术后早期他克莫司药物浓度,观察移植术后排斥反应发生情况。结果:术后第1周和第2周他克莫司浓度分别为(5.14±2.68)ng/mL和(8.41±5.73)ng/mL。16.7%(2/12)患者发生细胞性排斥。结论:肝移植术前使用PD-1抑制剂的肝癌患者,其移植术后排斥反应的发生率未见明显增加。
Objective:To observe the effect of PD-1 inhibitor treatment before liver transplantation on posttransplant rejection in liver cancer patients.Methods:The data of 12 patients with liver cancer who received PD-1 inhibitor before liver transplantation between January 1 and December 31,2019 in Zhongshan Hospital,Fudan University were analyzed.The concentration of tacrolimus in the early postoperative period were detected and the occurrence of rejection after transplantation were observed.Results:The tacroliums concentration at 1week or 2 week after liver transplantation were(5.14±2.68)ng/mL and(8.41±5.73)ng/mL.The incidence of rejection after liver transplantation was only 16.7%(2/12).Conclusions:The incidence of rejection after liver transplantation is not significantly increased in patients with liver cancer who use PD-1 inhibitors before liver transplantation.
作者
崔春晓
杨柳晓
王颖
黄俊峰
黄晓武
樊嘉
周俭
王婷
CUI Chun-xiao;YANG Liu-xiao;WANG Ying;HUANG Jun-feng;HUANG Xiao-wu;FAN Jia;ZHOU Jian;WANG Ting(Liver Transplantation Intensive Care Unit,Zhongshan Hospital,Fudan University,Shanghai 200032,China;Department of Liver Surgery and Transplantation,Liver Cancer Institute, Zhongshan Hospital,Fudan University,Shanghai 200032,China)
出处
《中国临床医学》
2020年第3期444-447,共4页
Chinese Journal of Clinical Medicine
基金
国家自然科学基金(81972232).
关键词
肝移植
PD-1抑制剂
排斥
肝癌
liver transplantation
PD-1 inhibitor
rejection
liver cancer
